On June 10, 2016 Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) reported that the United States District Court for the District of Delaware has ruled in favor of Teva in the Company’s patent infringement lawsuit against Hetero USA, Inc., InnoPharma Inc., Hospira Inc., Sagent Pharmaceuticals Inc., and Accord Healthcare Inc., regarding Teva’s TREANDA (bendamustine hydrochloride) for Injection (Filing, 6-K, Teva, JUN 10, 2016, View Source [SID:1234513199]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At trial, the defendants alleged that certain claims of U.S. Patents 8,436,190; 8,609,863; 8,791,270; and 8,895,756, listed in the Orange Book for TREANDA, are invalid. The defendants had previously stipulated to infringement of certain claims of these patents. Today the court issued a ruling affirming the validity of the relevant claims of all four patents. As a result, we expect that the court will enter an order enjoining the defendants from launching their respective generic versions of TREANDA until patent expiry in 2026.

"Teva is very pleased that the court has upheld the validity of its patents for the lyophilized formulation of TREANDA," said Rob Koremans, M.D., President and CEO of Teva Global Specialty Medicines. "This ruling is a testament to the strength of Teva’s intellectual property and commitment to defending our bendamustine franchise."